Two vaccine candidates designed for the Ebola virus behind the current outbreak in the Democratic Republic of the Congo are set to join the Tumaini clinical trial, following a recommendation from independent experts convened by the World Health Organization.
The decision matters because the candidates are being evaluated specifically against Bundibugyo virus disease. Existing Ebola vaccines have transformed the response to outbreaks caused by Zaire ebolavirus, but protection cannot simply be assumed across different Ebola virus species. The new trial is intended to generate evidence during an active outbreak, when speed and scientific rigor have to work together.
Which vaccines are entering the trial?
The two candidates are ChAdOx1, developed by the University of Oxford with the Serum Institute of India, and Moderna’s mRNA-1469. WHO says its Technical Advisory Group on Candidate Vaccine Prioritization reviewed preclinical and early clinical evidence before recommending both for further evaluation. Enrollment will begin only after the required national approvals.
This is not a declaration that either vaccine is effective. A candidate entering a clinical trial has passed an evidence threshold that justifies study in people under a defined protocol; efficacy and safety still have to be established through the trial.
How the Tumaini design works
Tumaini is a multi-candidate platform trial. Instead of building a new study from the ground up for every product, researchers can evaluate several candidates within one common structure. The vaccine arm uses ring vaccination: contacts of a person with confirmed disease, and potentially contacts of those contacts, are organized into groups around each case.
Ring vaccination has a practical public-health purpose. It focuses research and protection efforts where exposure risk is highest while helping teams measure whether vaccination changes the likelihood of disease. WHO reported that four vaccination rings were already in place and that additional rings were being prepared.
Why treatment research is running in parallel
Vaccination is only one part of an outbreak response. The WHO-sponsored PARTNERS trial is also examining potential treatments for people with confirmed Bundibugyo virus disease. The study includes the monoclonal antibody MBP134, the antiviral remdesivir and a combination of the two. Another antibody, maftivimab, is expected to be added, while a separate study is assessing obeldevisir after exposure.
Running vaccine and treatment studies at the same time recognizes two different needs: preventing disease among people at risk and improving survival among those already infected. Neither research track replaces surveillance, laboratory confirmation, infection prevention, safe care or community engagement.
What happens next
WHO expects initial findings from treatment studies in the coming months and vaccine-trial results in early 2027. Until those results are available, the accurate description is that the products are candidates under evaluation—not approved solutions.
The larger lesson is operational. Outbreak research can move quickly when protocols, manufacturing partnerships, ethics review pathways and local scientific leadership are prepared in advance. The trial is led by the DRC’s Institut National de Recherche Biomédicale with international partners, but the evidence will depend on the participation and protection of affected communities.
Source: World Health Organization news release, 4 November 2026.
This article is for general information and does not replace medical or public-health guidance.
